middle.news
Mesoblast Advances FDA Approval for Heart Failure and Expands Ryoncil Use
10:32am on Thursday 12th of June, 2025 AEST
•
Healthcare
Read Story
Mesoblast Advances FDA Approval for Heart Failure and Expands Ryoncil Use
10:32am on Thursday 12th of June, 2025 AEST
Key Points
FDA alignment on Revascor accelerated approval pathway
Upcoming pivotal trial for Ryoncil label extension to adults
Ryoncil US commercial launch exceeds hospital onboarding targets
Expanded payer coverage for Ryoncil across 37 states
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE